We have commenced a large project to express both spike and nucleoprotein of COVID-19, and other coronaviruses - SARS, MERS, OC43, 229E, NL63, and HKU1.
The antigens will be provided to Burnet’s Global Health Diagnostics Development Group for development of a COVID-19 point-of-care (PoC) diagnostic.
Our lab will contribute to PoC test development by providing novel technology to alter antigen structure and enhance sensitivity of PoC tests that can be monitored by Biolayer interferometry.
The Viral Entry and Vaccines Group have extensive expertise in the expression of viral glycoprotein antigens, manipulation of protein sequences to enhance expression and alter folding characteristics and optimisation of purification methods to increase yield and purity.
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung people and we offer our respects to their Elders past and present. We recognise and respect the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples of this land.
Oops!
It looks like something may have gone wrong, and some of the resources required to load the page may not have loaded correctly.
